Samsung Bioepis - a spin-off sweetener? | Lex
- 5 years ago
► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
Drugmaker Samsung Bioepis is looking to list in New York, saying it needs to fund its development of biosimilar drugs. But with a large and lucrative biotech market, why would Samsung spin off the company? Lex's Oliver Ralph asks Lucy Colback.
► FT Business: http://bit.ly/1KUK08s
► Lex: http://bit.ly/1I14JZF
► Bid For Dragon Oil, too low?: http://bit.ly/1eu8dbu
For more video content from the Financial Times, visit http://www.FT.com/video
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
Drugmaker Samsung Bioepis is looking to list in New York, saying it needs to fund its development of biosimilar drugs. But with a large and lucrative biotech market, why would Samsung spin off the company? Lex's Oliver Ralph asks Lucy Colback.
► FT Business: http://bit.ly/1KUK08s
► Lex: http://bit.ly/1I14JZF
► Bid For Dragon Oil, too low?: http://bit.ly/1eu8dbu
For more video content from the Financial Times, visit http://www.FT.com/video
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes